Market accessOfficial

Danish regulator withdraws Rapamune oral solution supply difficulty notice for Pfizer

🇩🇰 DKMA · Tue 27 Oct 2026

The Danish Medicines Agency says there is no shortage of Pfizer's Rapamune 1 mg/ml oral solution after all, reversing an earlier supply notice.

The Danish Medicines Agency (DKMA) has reversed an earlier notice about Rapamune (sirolimus) 1 mg/ml oral solution, stating that there are no supply problems with the product from Pfizer ApS after all.

The original notice was published on 19 October 2026 and updated on 27 October 2026. The updated entry in the agency's supply notification list is marked 'not a shortage after all'. It had cited delays at the manufacturer as the reason for the supply difficulty.

The listing identifies the product as Rapamune 1 mg/ml oral solution, with sirolimus as the active substance and ATC code L04AH01. No expected period of disruption is given. The agency does not describe any mitigation measures or alternative sourcing arrangements.

DKMA directs anyone with questions about the current status to contact the company, Pfizer ApS.

What it means for your team

  • Teams that logged the 19 October notice as a live supply risk for Rapamune oral solution in Denmark should update their records to reflect the withdrawal.
  • No alternative sourcing or mitigation action is indicated by the agency for this product.
  • Questions about current availability should go to Pfizer ApS, as DKMA advises, rather than to the regulator.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →